esophagogastric junction adenocarcinoma
Conditions
Interventions
Group A:Ivor-Lewis resection after neoadjuvant chemotherapy
Group B:Left thoracic resection after neoadjuvant chemotherapy
Sponsors
Department of Esophageal Cancer, Tianjin Medical University Cancer Institute and Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Esophagogastric junction adenocarcinoma with pathologic diagnosis; 2. Siewert I and Siewert II Esophagogastric junction adenocarcinoma; 3. Tumor stage belongs to cT1bN+ or cT2-T4aN0-N+; 4. ECOG more that 0-1. More than 12 months of expected suvival; 5. Absolute white blood cells count >=4.0*10^9/L, neutrophil >=1.5*10^9/L, platelets >=100.0*10^9/L, hemoglobin >=90g/L, and normal functions of liver and kidney; 6. Signed informed consent document on file.;Inclusion criteria: 1. Esophagogastric junction adenocarcinoma with pathologic diagnosis; 2. Siewert I and Siewert II Esophagogastric junction adenocarcinoma; 3. Tumor stage belongs to cT1bN+ or cT2-T4aN0-N+; 4. ECOG more that 0-1. More than 12 months of expected suvival; 5. Absolute white blood cells count >=4.0*10^9/L, neutrophil >=1.5*10^9/L, platelets >=100.0*10^9/L, hemoglobin >=90g/L, and normal functions of liver and kidney; 6. Signed informed consent document on file.;Inclusion criteria: 1. Esophagogastric junction adenocarcinoma with pathologic diagnosis; 2. Siewert I and Siewert II Esophagogastric junction adenocarcinoma; 3. Tumor stage belongs to cT1bN+ or cT2-T4aN0-N+; 4. ECOG more that 0-1. More than 12 months of expected suvival; 5. Absolute white blood cells count >=4.0*10^9/L, neutrophil >=1.5*10^9/L, platelets >=100.0*10^9/L, hemoglobin >=90g/L, and normal functions of liver and kidney; 6. Signed informed consent document on file.;Inclusion criteria: 1. Esophagogastric junction adenocarcinoma with pathologic diagnosis; 2. Siewert I and Siewert II Esophagogastric junction adenocarcinoma; 3. Tumor stage belongs to cT1bN+ or cT2-T4aN0-N+; 4. ECOG more that 0-1. More than 12 months of expected suvival; 5. Absolute white blood cells count >=4.0*10^9/L, neutrophil >=1.5*10^9/L, platelets >=100.0*10^9/L, hemoglobin >=90g/L, and normal functions of liver and kidney; 6. Signed informed consent document on file.;Inclusion criteria: 1. Esophagogastric junction adenocarcinoma with pathologic diagnosis; 2. Siewert I and Siewert II Esophagogastric junction adenocarcinoma; 3. Tumor stage belongs to cT1bN+ or cT2-T4aN0-N+; 4. ECOG more that 0-1. More than 12 months of expected suvival; 5. Absolute white blood cells count >=4.0*10^9/L, neutrophil >=1.5*10^9/L, platelets >=100.0*10^9/L, hemoglobin >=90g/L, and normal functions of liver and kidney; 6. Signed informed consent document on file.
Exclusion criteria
Exclusion criteria: 1. Patients with prior treatment for esophageal cancer; 2. With a prior malignancy tumor; 3. Can not sign informed consent document on file for psychological, familial and societal factors.;Exclusion criteria: 1. Patients with prior treatment for esophageal cancer; 2. With a prior malignancy tumor; 3. Can not sign informed consent document on file for psychological, familial and societal factors.;Exclusion criteria: 1. Patients with prior treatment for esophageal cancer; 2. With a prior malignancy tumor; 3. Can not sign informed consent document on file for psychological, familial and societal factors.;Exclusion criteria: 1. Patients with prior treatment for esophageal cancer; 2. With a prior malignancy tumor; 3. Can not sign informed consent document on file for psychological, familial and societal factors.;Exclusion criteria: 1. Patients with prior treatment for esophageal cancer; 2. With a prior malignancy tumor; 3. Can not sign informed consent document on file for psychological, familial and societal factors.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 3-year overall survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| progression-free survival;Recurrence-free survival;pathological response rate;R0 resection rate;lymph node dissection;postoperative major complications; | — |
Countries
China
Contacts
Public ContactZhentao Yu;Zhentao Yu;Zhentao Yu;Zhentao Yu;Zhentao Yu ;;;;
Tianjin Medical University Cancer Institute and Hospital;Tianjin Medical University Cancer Institute and Hospital;Tianjin Medical University Cancer Institute and Hospital;Tianjin Medical University Cancer Institute and Hospital;Tianjin Medical University Cancer Institute and Hospital
Outcome results
None listed